The risk of cytotoxic drugs during pregnancy

Scandinavian Journal of Rheumatology, Supplement

Volumn 27, Issue 107, 1998, Pages 133-135

  Ramsey Goldman, R ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Arthritis Division   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; METHOTREXATE; ALKYLATING AGENT; ANTIMETABOLITE;

BIRTH DEFECT; CARDIOVASCULAR MALFORMATION; CONFERENCE PAPER; FEMALE; HUMAN; INTRAUTERINE GROWTH RETARDATION; KIDNEY AGENESIS; MULTIPLE MALFORMATION SYNDROME; PANCYTOPENIA; PREGNANCY; PRIORITY JOURNAL; RISK; SKELETON MALFORMATION; SKULL DEFECT; URETER MALFORMATION; PREGNANCY COMPLICATION; REVIEW; RHEUMATIC DISEASE;

ALKYLATING AGENTS; ANTIMETABOLITES; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; RHEUMATIC DISEASES;

EID: 0031718693     PISSN: 03013847     EISSN: None     Source Type: Journal    
DOI: 10.1080/03009742.1998.11720788     Document Type: Conference Paper

References (31)

1. Fujii TM, Kowa Y. [Teratogenesis of azathioprine (Imuran) in mice and rats]. Oyo Yakuri 1968; 2:401.
2. Githens JH, Rosencrantz JG, Tunnock SM. Teratogenic effects of azathioprine (Imuran). J Pediatr 1965; 66:962-3.
3. Tuchman-Duplessis H, Mercier-Parot L. Production de malformations des membres chez le lapin par administrations d'un antimetabolite: l'azathioprine. CR Acad Sci YEAR??? 259:3648-51.
4. Saarikoski S, Seppala M. Immunosuppression during pregnancy; transmission of azathioprine and its metabolites from the mother to the fetus. Am J Obstet Gynecol 1973; 115:1100-6.
5. Rudolph JE, Schweizer RT, Bartkus SA. Pregnancy in renal transplant patients. Transplantation 1979; 27:26-9.
6. The Registration Committee of the European Dialysis and Transplant Association. Successful pregnancies in women treated by dialysis and kidney transplantation. Br J Obstet Gynaecol 1980; 87:839-45
7. Ramsey-Goldman R, Mientus JM, Kutzer JE, Mulvihill JJ, Medsger J TA. Pregnancy outcome in women with systemic lupus erythematosus treated with immunosuppressive drugs. J Rheumatol 1993; 20:1152-7.
8. Davison JM et al. Maternal azathioprine therapy and depressed hematopoiesis in the babies of renal allograft patients. Br J Obstet Gynaecol 1985; 92:233-9.
9. Monie IW. Chlorambucil-induced abnormalities of urogenital system of rat fetuses. Anat Rec 1961; 139:145.
10. Brummett ES, Johnson EM. Morphological alterations in the developing fetal rat limb due to maternal injection of chlorambucil. Teratology 1979; 20:279-88.
11. Sokal JE, Lessmann EM. Effects of cancer chemotherapeutic agents on the human fetus. JAMA 1960; 172:1765-71.
12. Shotton D, Monie IW. Possible teratogenic effect of chlorambucil on a human fetus. JAMA 1963; 186:74-5.
13. Steege JF, Caldwell DS. Renal agenesis after first trimester exposure to chlorambucil. South Med J 1980; 73:1414-5.
14. David J, Vouyiouka O, Ansell BM, Hall A, Woo P. Amyoidosis in juvenile chronic arthritis: a morbidity and mortality study. Clin Exp Rheumatol 1993; 11:85-90.
15. Chaube S, Kury G, Murphy ML. Teratogenic effects of cyclophosphamide in the rat. Cancer Chemother Biol Response Modif 1967; 51:363-76.
16. Fritz H, Hess R. Effects of cyclophosphamide on embryonic development in the rabbit. Agents Actions 1971; 2:83-6.
17. Wilk AL, McClure HM, Horigan EA. Induction of craniofacial malformations in the rhesus monkey with cyclophosphamide. Teratology 1978; 17:24A.
18. Kirshon B, Wasserstrum N, Wilis R, Herman GE, McCabe ERB. Teratogenic effects of first-trimester cyclophosphamide therapy. Obstet Gynecol 1988; 72:462-4.
19. Martinez-Rueda JO, Arce-Salinas CA, Kraus A, Alcocer-Varela J, Alarcon-Segovia D. Factors associated with fetal losses in severe systemic lupus erythematosus. Lupus 1996; 5:113-9.
20. Pizzuto J et al. Treatment of acute leukemia during pregnancy: presentation of nine cases. Cancer Treat Rep 1980; 64:679-83.
21. Schmid BP. Monitoring of organ formation in rat embryos after in vitro exposure to azathioprine, mercaptopurine, methotrexate, or cyclosporine A. Toxicology 1984; 31:9-21.
22. Skalko RG, Gold MP. Teratogenicity of methotrexate in mice. Teratology 1974; 9:159-64.
23. Zamenhof S. Differential effects of antifolate on the development of brain parts in chick embryos. Growth 1985; 49:28-33.
24. Adams CE, Hay MF, Lutwak-Mann C. The actions of various agents on the rabbit embryo. Journal of Embryology and Experimental Morphology 1961; 9:468-91.
25. Wilson JG et al. Comparative distribution and embryotoxicity of methotrexate in pregnant rats and Rhesus monkeys. Teratology 1979; 19:71-80.
26. Briggs, Freeman, Yaffee. Drags in Pregnancy and Lactation. 3rd ed. Baltimore: Williams and Wilkins, 1990.
27. Kozlowski RD, Steinbrunner JV, MacKenzie AH, Clough JD, Wilke WS, Segal AM. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 1990; 88:589-92.
28. Buckley LM, Bullaboy CA, Leichtman L, Marquez M. Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheum 1998; 40:971-3.
29. Østensen M. Treatment with low dose methotrexate in early pregnancy. Rheumatology in Europe 1998; 26(Suppl. 2):40.
30. Tokuda M, Kurata N, Mizoguchi A, Inoh M, Seto K, Kinashi M, et al. Effect of low-dose cyclosporin A on systemic lupus erythematosus disease activity. Arthritis Rheum 1994 April; 37:551-8.
31. Bower C, Stanley FJ. Dietary folate as a risk factor for neural-tube defects: evidence from a case-control study in Western Australia. Med J Aust 1989; 150:613-9.